HDAC/CD13-IN-1
HDAC/CD13-IN-1 (Compound 12) is a HDAC/CD13 inhibitor (IC50: 0.34 μM for hCD13, 0.53 μM for porcine CD13, 0.03, 0.06, 0.02 μM for HDAC1/2/3) . HDAC/CD13-IN-1 inhibits MV4-11, K562, Jeko-1, and HL60 cell proliferation (IC50: 0.25-2.04 μM) . HDAC/CD13-IN-1 induces cancer cell apoptosis. HDAC/CD13-IN-1 has anti-metastasis and anti-invasion efficacy[1].
Product Specifications
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hdac-cd13-in-1.html
Solubility
10 mM in DMSO
Smiles
CC(C)C[C@H](NC([C@@H](O)[C@H](N)CC1=CC=CC=C1)=O)C(NCC2=CC=C(C(NNCCC)=O)C=C2)=O.Cl.Cl
Molecular Formula
C27H41Cl2N5O4
Molecular Weight
570.55
References & Citations
[1]Jia G, et al. Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer. Eur J Med Chem. 2023 Nov 15;260:115752.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K016-F1 2 Plates
Butyrylcholinesterase (BChE) Fluorescent Activity Kit
Sign In for Pricing
View Details